RNTX Rein Therapeutics, Inc.
Rein Therapeutics, Inc. (RNTX) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.5% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Rein Therapeutics, Inc.
Rein Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein Therapeutics, formerly known as Aileron Therapeutics Inc., is based in AUSTIN, Texas.
Sector
Healthcare
Industry
Biotechnology